LSB - LakeShore Biopharma Co., Ltd.
2.5441
0.164 6.450%
Share volume: 5,401
Last Updated: Tue 04 Feb 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.37%
PREVIOUS CLOSE
CHG
CHG%
$2.38
0.18
0.08%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.77%
1 Month
-28.34%
3 Months
18.33%
6 Months
446.65%
1 Year
536.03%
2 Year
371.13%
Key data
Stock price
$2.54
DAY RANGE
$2.31 - $2.54
52 WEEK RANGE
$0.36 - $5.70
52 WEEK CHANGE
$536.02
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Hui Shao and Dave Chenn
Region: US
Website: www.ysbiopharma.com
Employees: 773
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: www.ysbiopharma.com
Employees: 773
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.
Recent news